Collectively, these results demonstrated that blocking PVRIG elicited potent NK cell activation first, followed by T-cell activation, resulting in potent systemic antitumor immunity against tumors and tumor growth delay via both cytotoxic TIL activation and exhaustion prevention. The gene discussed is PVRIG; the disease is neoplasm.